Literature DB >> 908764

Release of platelet constituents by monosodium urate crystals.

M H Ginsberg, F Kozin, M O'Malley, D J McCarty.   

Abstract

The release of human platelet constituents by the etiologic agent of gout, the monosodium urate crystal, is described here. In suspensions of washed platelets, response to urate crystals proceeded in two phases: A secretory phase involved the rapid active release of serotonin, ATP, and ADP with little loss of lactic dehydrogenase or beta-glucuronidase. A lytic phase involved the slower loss of all platelet constituents. Both phases were inhibited by iodoacetate plus dinitrophenol, suggesting an energy requirement. In ultrastructural studies, lysis of washed platelets which appeared to contain crystals was seen. Urate crystals were also shown to induce serotonin release and platelet lysis in citrated platelet-rich plasma. Since urate crystals are deposited at a variety of sites, urate crystal-platelet interaction in vivo is a possibility. Such interactions, leading to release of platelet constituents, might contribute to gouty inflammation or to enhanced atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908764      PMCID: PMC372451          DOI: 10.1172/JCI108880

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID.

Authors:  O D RATNOFF; J D CRUM
Journal:  J Lab Clin Med       Date:  1964-03

2.  PLATELET SEQUESTRATION IN MAN. I. METHODS.

Authors:  R H ASTER; J H JANDL
Journal:  J Clin Invest       Date:  1964-05       Impact factor: 14.808

3.  STUDY OF PLATELET ADHESIVENESS AND AGGREGATION, WITH LATEX PARTICLES.

Authors:  M F GLYNN; H Z MOVAT; E A MURPHY; J F MUSTARD
Journal:  J Lab Clin Med       Date:  1965-02

4.  THE INFLAMMATORY PROCESS IN ACUTE GOUTY ARTHRITIS. I. ACTIVATION OF HAGEMAN FACTOR BY SODIUM URATE CRYSTALS.

Authors:  R W KELLERMEYER; R T BRECKENRIDGE
Journal:  J Lab Clin Med       Date:  1965-02

5.  STUDIES ON PLATELET FACTOR-3 AVAILABILITY.

Authors:  T H SPAET; J CINTRON
Journal:  Br J Haematol       Date:  1965-05       Impact factor: 6.998

6.  THE KAOLIN CLOTTING TIME OF PLATELET-RICH PLASMA: A TEST OF PLATELET FACTOR-3 AVAILABILITY.

Authors:  R M HARDISTY; R A HUTTON
Journal:  Br J Haematol       Date:  1965-05       Impact factor: 6.998

7.  A comparison of the duration of local anti-inflammatory effect of several adrenocorticosteroid esters--a bioassay technique.

Authors:  D J MCCARTY; J S FAIRES
Journal:  Curr Ther Res Clin Exp       Date:  1963-05

8.  Specific vascular changes in gout.

Authors:  E F TRAUT; A A KNIGHT; P B SZANTO; E W PASSERELLI
Journal:  J Am Med Assoc       Date:  1954-10-09

9.  The release of histamine and 5-hydroxytryptamine (serotonin) from platelets by antigen-antibody reactions (in vitro).

Authors:  J H HUMPHREY; R JAQUES
Journal:  J Physiol       Date:  1955-04-28       Impact factor: 5.182

10.  BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.

Authors:  J F MUSTARD; E A MURPHY; M A OGRYZLO; H A SMYTHE
Journal:  Can Med Assoc J       Date:  1963-12-14       Impact factor: 8.262

View more
  33 in total

Review 1.  New knowledge of the pathogenesis of gout.

Authors:  J T Scott
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

2.  Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study.

Authors:  Shih-Yang Chen; Ching-Lang Chen; Ming-Lai Shen
Journal:  Clin Rheumatol       Date:  2006-05-11       Impact factor: 2.980

3.  Identification and quantitation of platelet-associated fibronectin antigen.

Authors:  E F Plow; C Birdwell; M H Ginsberg
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

Review 4.  Uric Acid and Cardiovascular Disease: An Update.

Authors:  Maria Lorenza Muiesan; Claudia Agabiti-Rosei; Anna Paini; Massimo Salvetti
Journal:  Eur Cardiol       Date:  2016-08

5.  High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients.

Authors:  Tanja Antunovic; Aleksandra Stefanovic; Marina Ratkovic; Branka Gledovic; Najdana Gligorovic-Barhanovic; Dragica Bozovic; Jasmina Ivanisevic; Milica Prostran; Marina Stojanov
Journal:  Int Urol Nephrol       Date:  2012-07-25       Impact factor: 2.370

6.  Serum Uric Acid Levels and Risk of Intracranial Atherosclerotic Stenosis: A Cross-Sectional Study.

Authors:  Lin Li; Jun-Xia Zhu; Xiao-He Hou; Ya-Hui Ma; Wei Xu; Chen-Chen Tan; Fu-Rong Sun; Hong-Qi Li; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2020-02-08       Impact factor: 3.911

Review 7.  Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?

Authors:  Zohreh Soltani; Kashaf Rasheed; Daniel R Kapusta; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

8.  The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease.

Authors:  Peter Higgins; Jesse Dawson; Matthew Walters
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-11-04

9.  Thrombin increases expression of fibronectin antigen on the platelet surface.

Authors:  M H Ginsberg; R G Painter; J Forsyth; C Birdwell; E F Plow
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

10.  Elevated uric acid increases the risk for kidney disease.

Authors:  Rudolf P Obermayr; Christian Temml; Georg Gutjahr; Maarten Knechtelsdorfer; Rainer Oberbauer; Renate Klauser-Braun
Journal:  J Am Soc Nephrol       Date:  2008-09-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.